All In Biotech

NDA 206356 · Swedish Orphan

Orfadin

Nitisinone · Oral · 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor

Orphan

Last checked: Nov 19, 2026Latest source record: May 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 22, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

3 Phase 3, 0 recruiting

FAERS reports

820

649 serious, 146 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

ORFADIN ® is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. ORFADIN is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. ( 1 )

Mechanism: Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ORFADIN · NITISINONE 4MG/ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitisinone" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • amino acid level increased128
  • liver transplant117
  • hepatocellular carcinoma61
  • alpha 1 foetoprotein increased52
  • treatment noncompliance49
  • cataract47
  • hepatic failure44
  • hepatic cirrhosis37
  • death35
  • lenticular opacities34
  • succinylacetone increased33
  • vomiting33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20055
200611
20077
200814
200918
201020
201128
201237
201314
201412
201530
201651
201769
201899
2019129
2020112
202140
202251
202319
202418
202516
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orfadin (Nitisinone)

2024 spending

$243K

Beneficiaries

n/a

49 claims

Per beneficiary

n/a

$111.93 per unit

View as table
YearSpending
2020$111,688
2021$334,339
2022$416,260
2023$317,274
2024$242,773

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Swedish Orphan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.